~~<i id='AAF8D8CC5D'><strike id='AAF8D8CC5D'><tt id='AAF8D8CC5D'><pre id='AAF8D8CC5D'></pre></tt></strike></i>~~

Home» Wikipedia» Wikipedia

Wikipedia

author：entertainment 2025-09-28 09:40:08 Page View：676

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hilary expected to bring catastrophic, life
Next article： At least 13 dead in Texas as scorching temps continue

explore

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

1:03JackSmith,thentheDepartmentofJustice'schiefofthePublicIntegritySection,posesforphotoattheDepartm

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Trump's false claims about Georgia's 2020 election long debunked

43:58FormerPresidentDonaldTrumpspeakswiththepressattheIowaPorkProducersboothduringthe2023IowaStateFa